THIS WEEK · NORTH AMERICA | |||||||||||||||||||
Co-owners, | |||||||||||||||||||
We've spun the wheel for the North America bucket and landed in Cambridge, Massachusetts, on a company that makes medicines for some of the rarest diseases on earth and collects a cheque every time a rival sells its drug. | |||||||||||||||||||
Before we dive in, a reminder of what the index itself has delivered over time. | |||||||||||||||||||
| |||||||||||||||||||
Biogen Inc. | |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
In many countries, a baby gets a hepatitis B jab within days of being born. Some of the science behind those vaccines came from a small Geneva start-up founded by a group of university professors in 1978. | |||||||||||||||||||
That start-up became Biogen. Today it makes medicines for the brain and nerves: multiple sclerosis, a rare disease that stops babies from lifting their heads, a rare one that takes away teenagers' balance, and Alzheimer's. | |||||||||||||||||||
| |||||||||||||||||||
A company of professors | |||||||||||||||||||
Biogen was one of the first biotech companies anywhere. Its founders were professors from Harvard, MIT, Edinburgh, Heidelberg and Zurich. Two of them later won Nobel prizes: Walter Gilbert in 1980, while he was running the company, and Phillip Sharp in 1993. | |||||||||||||||||||
The early breakthroughs were licensed to bigger drug makers rather than sold by Biogen itself. One was interferon, used against hepatitis and some cancers. The other was the hepatitis B vaccine technology, licensed to SmithKline Beecham in 1988. | |||||||||||||||||||
Biogen found its real business in the 1990s: multiple sclerosis (MS), a disease in which the immune system attacks the coating of the nerves. It usually strikes people in their 20s to 40s. Biogen built a string of MS treatments, from weekly injections to monthly infusions to a pill, Tecfidera, which became a blockbuster in the 2010s. | |||||||||||||||||||
What you actually own | |||||||||||||||||||
MS medicines. Still the biggest business, at ~$4.0 billion in 2025, but falling. Tysabri, a monthly infusion, is the steadiest. | |||||||||||||||||||
Rare diseases (~$2.2 billion). In 2016, Spinraza became the first approved treatment for spinal muscular atrophy, a genetic disease in which babies slowly lose the nerves that control their muscles. Before that, doctors had nothing to offer. Skyclarys is the first and only approved drug for Friedreich's ataxia, an inherited disease that slowly takes away balance and coordination, often starting in childhood. Biogen bought it with Reata in 2023 for $7.3 billion. Sales grew 36% last year. | |||||||||||||||||||
Alzheimer's. Leqembi, sold with Japan's Eisai, slows memory decline in early Alzheimer's by clearing a sticky protein from the brain. The effect is modest, but it is real. Since July, patients in the US can also start treatment with an injection pen at home instead of sitting in an infusion centre. | |||||||||||||||||||
Eyes and kidneys (new in 2026). In May, Biogen paid ~$5.6 billion for Apellis. Its main drug, Syfovre, is an eye injection for geographic atrophy, a late stage of age-related macular degeneration in which patches of the retina die and central vision fades. | |||||||||||||||||||
The royalty. Thanks to a 2003 merger with IDEC, the co-developer of the cancer drug Rituxan, Biogen earns a royalty on Ocrevus, the MS drug sold by Roche. So Biogen makes money from the very drug that competes with its own MS franchise: ~$1.4 billion last year. | |||||||||||||||||||
Racing the cliff | |||||||||||||||||||
We explained patent cliffs in edition #31 on Otsuka: when a patent expires, cheap copies arrive and sales collapse. Biogen's MS medicines have been going over that cliff one by one. Tecfidera sales fell 53% in the latest quarter. | |||||||||||||||||||
The obvious answer was Alzheimer's, and Biogen went all in. Its first Alzheimer's drug, Aduhelm, won a disputed approval in 2021 at a price of $56,000 a year. Doctors doubted it worked, Medicare refused to pay for it outside trials, and Biogen halved the price. In January 2024, it dropped the drug. | |||||||||||||||||||
Christopher Viehbacher, who became CEO in late 2022, changed course. Biogen cut ~$1 billion of costs, bought Reata and Apellis, and rebuilt its pipeline. Even so, before the Apellis deal analysts expected Biogen's earnings to be roughly flat through 2030. | |||||||||||||||||||
The turn came this year. In the second quarter of 2026, Biogen's newer medicines brought in $1.06 billion, up 24%, more than the old MS franchise at $767 million. It was the second quarter in a row. | |||||||||||||||||||
The numbers, in plain view | |||||||||||||||||||
Second-quarter revenue rose 3% to $2.74 billion. For 2026, Biogen now expects revenue to grow by a mid-single-digit percentage. In February, it expected a decline. | |||||||||||||||||||
Biogen has never paid a dividend. It spends its cash on deals instead, and the Apellis purchase took net debt to $6.8 billion, which it plans to pay down by the end of 2027. | |||||||||||||||||||
The other side of the ledger | |||||||||||||||||||
The MS decline is not over. Copies of Tecfidera are already on sale, and a copy of Tysabri was approved in the US and Europe in 2023. | |||||||||||||||||||
Much of Biogen's future depends on medicines that are still being tested. The first big result arrives by the end of this year, for a lupus drug called litifilimab. Lupus is a disease in which the immune system attacks the body's own skin, joints and organs. Three more results follow by autumn 2027. Even at this late stage, many drugs fail. | |||||||||||||||||||
Leqembi is shared with Eisai, which has the final say, and its benefit is modest, so take-up has been slow. US drug pricing is also a constant risk. | |||||||||||||||||||
| |||||||||||||||||||
| |||||||||||||||||||
|

